Get in Touch

KOL Call on Oncocyte’s Proprietary DetermaRx™ and DetermaIO™ Molecular Tests For Cancer Treatment Selection

Hosted by Oncocyte (NYSE: OCX) and LifeSci Advisors
Tuesday, December 15, 2020
11:00 AM - 12:30 PM EST



The call will feature a presentation by Key Opinion Leaders (KOLs) Johannes Kratz, MD, FACS (University of California at San Francisco) who will discuss the clinical opportunity for DetermaRx™, Medicare-reimbursed, and the first and only test for adjuvant treatment selection in surgically resected lung cancer patients, and Lajos Pusztai, MD, DPhil (Yale Cancer Center) who will discuss clinical evidence supporting DetermaIO™, Oncocyte’s gene expression test to predict response to first and second generation immunotherapies, including currently marketed immune-checkpoint inhibitors (ICIs). Close to 750,000 patients are eligible for ICI treatment annually in the United States alone. Drs. Kratz and Pusztai will be available to answer questions following the formal presentations.

Click on the Right To Register

Oncocyte's management team will also give an overview of their Determa RNA Platform strategy for cancer content to assist in critical clinical questions that today are unanswered. They will also provide an update on the commercialization strategy for both DetermaRx™ and DetermaIO™, two of the company’s initial growth engines from the Determa Platform approach. These two products together have a Served Available Market of well over $3B, and the ongoing market launches of these exciting tests will be primary growth drivers for 2021 as the company ramps up revenues and reduces its overall burn. Importantly, the clinical questions answered by these two proprietary approaches have already saved lives and reduced the cost of care, two paramount imperatives of Oncocyte’s Mission. 

If you would like to ask a question during the live Q&A, please submit your request HERE




About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. TheraSure is a trademark of Chronix Biomedical, Inc.

Oncocyte Forward Looking Statements

Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to the commercial launch of DetermaRx, development of DetermaIO, unexpected expenditures or assumed liabilities or other unanticipated difficulties resulting from acquisitions, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for Oncocyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize, and risks inherent in acquisitions such as failure to realize anticipated benefits, unexpected expenditures or assumed liabilities, unanticipated difficulties in conforming business practices including accounting policies, procedures and internal controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Key Takeaways
  • Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum
  • DetermaRx™ is a Medicare-reimbursed treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy.
  • DetermaIO™ is a novel tumor microenvironment classifier that measures expression levels of 27 genes and predicts response to immune checkpoint inhibitor therapies in multiple cancer types.
Media Gallery
Video Gallery
Files
Related Bios
Lajos Pusztai, MD, DPhil
Professor of Medicine at Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program.
View Full Bio>>
Johannes R. Kratz, M.D., FACP
Assistant Professor of Surgery Division of Adult Cardiothoracic Surgery Van Auken Endowed Chair in Thoracic Oncology Director, Minimally Invasive and Robotic Thoracic Surgery Associate Director, Thoracic Surgery Residency Program
View Full Bio>>
Doug Ross, M.D., Ph.D.
Chief Medical Officer
View Full Bio>>
Ronald Andrews
President and CEO
View Full Bio>>
Mitch Levine
Chief Financial Officer
View Full Bio>>
Padma Sundar
Senior Vice President, Commercial
View Full Bio>>
Contacts
Chelli Miller
chelli@contentcarnivores.com
219-921-6823